The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in Canada
- 1 May 1992
- journal article
- Published by Elsevier in Social Science & Medicine
- Vol. 34 (9) , 983-991
- https://doi.org/10.1016/0277-9536(92)90129-e
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Recombinant Human Erythropoietin: Factors to Consider in Cost-Benefit AnalysisAmerican Journal of Kidney Diseases, 1991
- Prognostic Implications of Echocardiographically Determined Left Ventricular Mass in the Framingham Heart StudyNew England Journal of Medicine, 1990
- Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.BMJ, 1990
- Treatment of the Anemia of Progressive Renal Failure with Recombinant Human ErythropoietinNew England Journal of Medicine, 1989
- Recombinant Human Erythropoietin Treatment in Pre-Dialysis PatientsAnnals of Internal Medicine, 1989
- The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietinKidney International, 1989
- Transfusion-Associated Hepatitis and AIDSNew England Journal of Medicine, 1987
- Correction of the Anemia of End-Stage Renal Disease with Recombinant Human ErythropoietinNew England Journal of Medicine, 1987
- A Cost-Effectiveness Analysis of Continuous Ambulatory Peritoneal Dialysis and Hospital HemodialysisMedical Decision Making, 1984
- Should donor blood be screened for elevated alanine aminotransferase levels? A cost-effectiveness analysisJAMA, 1984